Related Experiment Video
Updated: Jun 15, 2025

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
Published on: August 20, 2016
Inhibition of Experimental Corneal Neovascularization by the Tight Junction Protein ZO-1
Qingying Yao1, Hongya Wu2, Hang Ren1
1Department of Ophthalmology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Abstract:
Purpose: To explore the effects of the tight junction protein zonula occludens 1 (ZO-1) on experimental corneal neovascularization (CNV). Methods: CNV models were established in the left eyes of BALB/c mice using NaOH. Anti-ZO-1 neutralizing antibody was topically applied to the burnt corneas after modeling thrice a day for 1 week. CD31 expression was analyzed to calculate the ratio of CNV number to area using a corneal whole-mount fluorescent immunohistochemical assay. Messenger ribonucleic acid (mRNA) and protein expression levels of ZO-1, vascular endothelial growth factor (VEGF), interleukin (IL)-1β, IL-6, IL-8, IL-18, monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor alpha (TNF-α), phosphorylated protein kinase C (pPKC), and clusterin in burned corneas were detected by reverse transcriptase polymerase chain reaction (PCR) and western blot analyses. Infiltration of neutrophils, macrophages, and progenitor cells was examined by flow cytometry. Results: CNV was obviously greater in 45 s than in 15 s alkali injury group. In another experiment, CNV was obviously greater in the ZO-1 antibody group than in the vehicle-treated group. Corneal mRNA and protein expression levels of VEGF, IL-1β, IL-6, IL-8, IL-18, and MCP-1 were significantly higher in the ZO-1 antibody group than in the control group. Infiltration of neutrophils, macrophages, and progenitor cells was significantly greater in the ZO-1 antibody group than in the control group. TNF-α expression was much higher in 45 s than in 15 s alkali injury group. However, protein expression of pPKC and clusterin was much lower in 45 s than in 15 s alkali injury group. Conclusions: Anti-ZO-1 neutralizing antibody-treated mice exhibited enhanced alkali-induced CNV through enhanced intracorneal infiltration of progenitor and inflammatory cells.
Insights
Blocking zonula occludens 1 (ZO-1) with an antibody worsened experimental corneal neovascularization (CNV) by increasing inflammatory cell infiltration. This suggests ZO-1 plays a protective role in alkali-induced CNV.
Area of Science:
- Ophthalmology
- Immunology
- Molecular Biology
Background:
- Corneal neovascularization (CNV) is a pathological process involving the growth of new blood vessels into the cornea.
- Tight junction proteins, such as zonula occludens 1 (ZO-1), play critical roles in maintaining epithelial barrier integrity.
- The specific role of ZO-1 in the pathogenesis of experimental corneal neovascularization remains incompletely understood.
Purpose of the Study:
- To investigate the effect of zonula occludens 1 (ZO-1) on the development of experimental corneal neovascularization (CNV).
- To elucidate the underlying mechanisms by which ZO-1 influences CNV, including inflammatory cell infiltration and cytokine expression.
Main Methods:
- Corneal neovascularization (CNV) models were induced in BALB/c mice using alkali injury.
- Anti-ZO-1 neutralizing antibody was administered topically to assess its impact on CNV.
- Corneal whole-mount fluorescent immunohistochemistry, RT-PCR, western blot, and flow cytometry were employed to analyze CNV, ZO-1, VEGF, inflammatory markers, and cell infiltration.
Main Results:
- Treatment with anti-ZO-1 neutralizing antibody significantly enhanced alkali-induced corneal neovascularization (CNV).
- Elevated mRNA and protein levels of pro-inflammatory factors (VEGF, IL-1β, IL-6, IL-8, IL-18, MCP-1) were observed in the ZO-1 antibody group.
- Increased infiltration of neutrophils, macrophages, and progenitor cells was detected in corneas treated with anti-ZO-1 antibody.
Conclusions:
- Blocking zonula occludens 1 (ZO-1) exacerbates experimental corneal neovascularization (CNV).
- Anti-ZO-1 antibody treatment promotes CNV by enhancing the infiltration of inflammatory and progenitor cells into the cornea.
- ZO-1 appears to have a protective role in mitigating alkali-induced corneal neovascularization.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Tight Junctions

